Previous 10 | Next 10 |
2023-10-10 07:30:00 ET Summary After years of buyout rumors, Mirati has finally received a buyout offer. The offer from Bristol-Myers Squibb was disappointing to shareholders who were anticipating a significant buyout premium. Although there is always a possibility of addition...
2023-10-09 13:10:55 ET More on Bristol-Myers Squibb Company , Mirati Therapeutics Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? ...
2023-10-09 13:04:02 ET Bristol-Myers Squibb Co (NYSE: BMY) has decided to spend up to $5.8 billion to acquire Mirati Therapeutics Inc (NASDAQ: MRTX). Shares of both companies are in the red at writing. Bristol-Myers will get to expand its footprint in oncology The all-cash trans...
2023-10-09 12:00:33 ET Summary Bristol-Myers Squibb has announced its acquisition of Mirati Therapeutics and its lead drug candidate KRAZATI for a potential value of $5.8 million. BMY paid a 52% premium to Mirati's share price with other Pharmas - e.g. Sanofi - rumored to be inter...
NEW YORK, NY / ACCESSWIRE / October 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc. (NASDA...
2023-10-09 09:56:59 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript 4 st...
2023-10-09 09:20:00 ET U.S. stock index futures on Monday pointed to a lower open, with the spotlight on geopolitical conflict following Israel's declaration of war on Hamas after a surprise attack. Wall Street's benchmark index on Friday eventually ended a tumultuous week with a ~0.5% ...
2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...
2023-10-09 06:48:53 ET Summary Crude oil and gold futures rise in response to the Israel-Hamas conflict. Analysts expect limited gains in crude oil prices unless the conflict escalates into a regional war. Bristol-Myers Squibb agrees to acquire Mirati Therapeutics for $4.8 bil...
2023-10-08 17:52:39 ET More on Mirati Therapeutics Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript As F...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...